desloratadine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
histamine-H1 receptor antagonists, tricyclic compounds	814	100643-71-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: SCH-34117 SCH 34117 desloratadine azomyr delopedil descarboethoxyloratadine descarboethoxyloratidine neoclarityn	major metabolite of loratadine Molecular weight: 310.83 Formula: C19H19ClN2 CLOGP: 3.83 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 24.92 ALOGS: -4.90 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

SCH-34117
SCH 34117
desloratadine
azomyr
delopedil
descarboethoxyloratadine
descarboethoxyloratidine
neoclarityn

major metabolite of loratadine

Molecular weight: 310.83
Formula: C19H19ClN2
CLOGP: 3.83
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 24.92
ALOGS: -4.90
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
5	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.23 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
fu (Fraction unbound in plasma)	0.15 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
Dec. 21, 2001	FDA	MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	179.66	12.58	128	16853	47837	63424204
Urticaria	100.57	12.58	168	16813	165634	63306407
Endocrine ophthalmopathy	74.46	12.58	20	16961	651	63471390
Nasal ulcer	68.21	12.58	25	16956	2279	63469762
Intentional overdose	61.60	12.58	87	16894	74065	63397976
Toxic shock syndrome	61.10	12.58	18	16963	824	63471217
Drug reaction with eosinophilia and systemic symptoms	58.87	12.58	58	16923	33778	63438263
Pruritus	53.94	12.58	215	16766	361238	63110803
Allergy test positive	52.75	12.58	15	16966	605	63471436
Erythema	52.55	12.58	133	16848	175618	63296423
Eyelid disorder	47.21	12.58	18	16963	1831	63470210
Hallucination, auditory	45.17	12.58	33	16948	12791	63459250
Toxic skin eruption	45.03	12.58	33	16948	12852	63459189
Hyponatraemia	44.78	12.58	95	16886	111805	63360236
Mean cell haemoglobin increased	42.29	12.58	19	16962	2924	63469117
Dermatitis bullous	42.08	12.58	27	16954	8481	63463560
Drug intolerance	40.43	12.58	16	16965	308645	63163396
Systemic lupus erythematosus	38.89	12.58	5	16976	208913	63263128
Haemangioma congenital	38.74	12.58	11	16970	441	63471600
Swelling of eyelid	37.93	12.58	18	16963	3138	63468903
Terminal dribbling	37.12	12.58	6	16975	11	63472030
Rheumatoid arthritis	36.96	12.58	11	16970	253808	63218233
Paranoia	36.55	12.58	28	16953	11651	63460390
Intentional self-injury	33.89	12.58	38	16943	25649	63446392
Cholestasis	32.92	12.58	40	16941	29394	63442647
Wound	32.68	12.58	3	16978	163260	63308781
Eczema	29.98	12.58	40	16941	32251	63439790
Drug ineffective	28.98	12.58	163	16818	1044602	62427439
Completed suicide	28.31	12.58	3	16978	145670	63326371
Cerebral thrombosis	27.80	12.58	12	16969	1679	63470362
Death	27.43	12.58	36	16945	374345	63097696
Face oedema	26.84	12.58	30	16951	20182	63451859
Dyslipidaemia	25.98	12.58	19	16962	7374	63464667
Therapeutic product effect decreased	25.30	12.58	10	16971	193177	63278864
Aggression	24.77	12.58	31	16950	23467	63448574
Oxalosis	24.44	12.58	5	16976	47	63471994
Type IV hypersensitivity reaction	24.44	12.58	13	16968	2885	63469156
Victim of chemical submission	24.38	12.58	8	16973	524	63471517
Hepatic cytolysis	24.20	12.58	25	16956	15382	63456659
Tooth injury	24	12.58	10	16971	1282	63470759
Gestational hypertension	23.70	12.58	12	16969	2405	63469636
Blood immunoglobulin E increased	23.58	12.58	14	16967	3835	63468206
Skin dystrophy	23.18	12.58	5	16976	62	63471979
Rash maculo-papular	22.96	12.58	35	16946	31861	63440180
Contraindicated product administered	22.93	12.58	15	16966	217633	63254408
Vitamin D decreased	22.51	12.58	20	16961	10222	63461819
Somnolence	22.45	12.58	101	16880	178584	63293457
Burn oral cavity	21.71	12.58	5	16976	85	63471956
Hyperkalaemia	21.64	12.58	46	16935	54157	63417884
Eye infection	21.45	12.58	21	16960	12124	63459917
Haemorrhagic erosive gastritis	21.22	12.58	7	16974	466	63471575
Acute kidney injury	20.81	12.58	131	16850	263284	63208757
Synovial cyst	20.25	12.58	19	16962	10414	63461627
Hepatocellular injury	19.64	12.58	30	16951	27351	63444690
Tongue oedema	18.92	12.58	13	16968	4573	63467468
Onycholysis	18.65	12.58	9	16972	1627	63470414
Swelling	18.63	12.58	28	16953	275350	63196691
Pain	18.63	12.58	119	16862	740509	62731532
Dermatitis exfoliative generalised	18.62	12.58	12	16969	3795	63468246
Arrhythmia	18.37	12.58	35	16946	38105	63433936
Hyperoxaluria	18.18	12.58	5	16976	178	63471863
Inflammatory bowel disease	18.16	12.58	12	16969	3961	63468080
Joint swelling	17.96	12.58	38	16943	327628	63144413
Pelvic pain	17.83	12.58	20	16961	13499	63458542
Abortion	17.74	12.58	10	16971	2486	63469555
Urticaria thermal	17.72	12.58	6	16975	433	63471608
Guttate psoriasis	17.46	12.58	6	16975	453	63471588
HLA-B*27 positive	17.41	12.58	5	16976	209	63471832
Myalgia	17.05	12.58	81	16900	146448	63325593
Flatulence	16.90	12.58	32	16949	34670	63437371
Psychotic disorder	16.82	12.58	27	16954	25685	63446356
Infection	16.80	12.58	22	16959	229151	63242890
Arthrodesis	16.67	12.58	10	16971	2791	63469250
Nightmare	16.64	12.58	23	16958	19171	63452870
Conjunctivitis allergic	16.52	12.58	7	16974	935	63471106
Drug dose titration not performed	16.45	12.58	6	16975	539	63471502
Urine oxalate increased	16.41	12.58	5	16976	257	63471784
Feeding disorder	16.33	12.58	19	16962	13343	63458698
Alopecia	16.21	12.58	42	16939	337494	63134547
Photosensitivity reaction	16.16	12.58	20	16961	14974	63457067
Arteriospasm coronary	15.79	12.58	11	16970	3957	63468084
Rash erythematous	15.74	12.58	35	16946	42475	63429566
Keratopathy	15.74	12.58	6	16975	610	63471431
Therapeutic product effect incomplete	15.52	12.58	7	16974	125049	63346992
Helicobacter infection	15.49	12.58	3	16978	92782	63379259
Subretinal haematoma	15.45	12.58	3	16978	21	63472020
Abortion spontaneous	15.43	12.58	37	16944	47158	63424883
Urticaria chronic	15.29	12.58	6	16975	659	63471382
Amnestic disorder	15.29	12.58	5	16976	324	63471717
Chronic spontaneous urticaria	15.14	12.58	7	16974	1150	63470891
Patent ductus arteriosus	15.11	12.58	11	16970	4239	63467802
Disease progression	15.03	12.58	7	16974	122751	63349290
Eosinophilia	15.02	12.58	24	16957	22732	63449309
Upper respiratory tract infection bacterial	14.99	12.58	4	16977	127	63471914
Intraocular haematoma	14.78	12.58	3	16978	27	63472014
Hypersensitivity pneumonitis	14.58	12.58	9	16972	2641	63469400
Pharyngeal oedema	14.30	12.58	18	16963	13703	63458338
Pericarditis	13.94	12.58	9	16972	131570	63340471
Linear IgA disease	13.64	12.58	7	16974	1444	63470597
Lip oedema	13.59	12.58	10	16971	3914	63468127
Systolic hypertension	13.55	12.58	5	16976	464	63471577
Pancoast's syndrome	13.38	12.58	3	16978	45	63471996
Metabolic acidosis	13.32	12.58	34	16947	45035	63427006
Nasal pruritus	13.30	12.58	5	16976	489	63471552
Anaphylactic shock	13.04	12.58	23	16958	23610	63448431
Eyelid erosion	12.97	12.58	3	16978	52	63471989
Skin disorder	12.90	12.58	26	16955	29481	63442560
Food intolerance	12.72	12.58	9	16972	3316	63468725
Coma	12.69	12.58	42	16939	64322	63407719
Synovitis	12.64	12.58	19	16962	186899	63285142

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Troponin T increased	55.44	14.04	21	8341	2350	34946219
Eosinophilia	54.03	14.04	47	8315	26175	34922394
Toxic skin eruption	52.10	14.04	33	8329	11352	34937217
Rash maculo-papular	46.89	14.04	45	8317	28406	34920163
Dermatitis bullous	44.55	14.04	25	8337	6897	34941672
Death	44.35	14.04	20	8342	398029	34550540
Hepatic haematoma	41.02	14.04	11	8351	399	34948170
N-terminal prohormone brain natriuretic peptide increased	39.17	14.04	17	8345	2698	34945871
Hyperkaliuria	38.21	14.04	8	8354	96	34948473
Xerosis	36.81	14.04	11	8351	593	34947976
Corneal abscess	35.47	14.04	6	8356	19	34948550
Intentional overdose	34.21	14.04	47	8315	43627	34904942
Urticaria	33.09	14.04	56	8306	62321	34886248
Electrocardiogram QT prolonged	31.96	14.04	44	8318	40908	34907661
Eczema	30.07	14.04	29	8333	18407	34930162
Pruritus	29.92	14.04	88	8274	141893	34806676
Rash pustular	28.10	14.04	17	8345	5391	34943178
Oral dysaesthesia	27.42	14.04	6	8356	90	34948479
Keratitis	27.37	14.04	11	8351	1440	34947129
Acute generalised exanthematous pustulosis	26.97	14.04	18	8344	6758	34941811
Angioedema	25.98	14.04	38	8324	37336	34911233
Miosis	25.72	14.04	20	8342	9515	34939054
Purpura	24.34	14.04	20	8342	10291	34938278
Blood immunoglobulin E decreased	24.28	14.04	5	8357	55	34948514
Prurigo	23.62	14.04	8	8354	647	34947922
Arrhythmia	22.87	14.04	35	8327	35773	34912796
Eyelid ptosis congenital	21.89	14.04	5	8357	92	34948477
Bulbar palsy	21.74	14.04	6	8356	243	34948326
Disease prodromal stage	21.44	14.04	4	8358	25	34948544
Oedema genital	21.34	14.04	7	8355	513	34948056
Cholangiocarcinoma	21.28	14.04	9	8353	1340	34947229
Type III immune complex mediated reaction	20.42	14.04	6	8356	305	34948264
Dermatitis psoriasiform	20.39	14.04	9	8353	1487	34947082
Dermatitis exfoliative	20.28	14.04	15	8347	6624	34941945
Rhabdomyolysis	20.19	14.04	48	8314	68115	34880454
Pemphigoid	18.78	14.04	16	8346	8650	34939919
Wrong product administered	18.46	14.04	13	8349	5321	34943248
Spermatic cord disorder	17.86	14.04	3	8359	9	34948560
Retinopathy	17.63	14.04	9	8353	2055	34946514
Hyperlipasaemia	17.53	14.04	6	8356	501	34948068
Myoglobin blood increased	17.00	14.04	10	8352	3013	34945556
Rhinitis allergic	16.91	14.04	10	8352	3040	34945529
Purulent pericarditis	16.04	14.04	3	8359	19	34948550
Hypertrophic cardiomyopathy	15.89	14.04	7	8355	1150	34947419
Intentional self-injury	15.88	14.04	18	8344	13753	34934816
Vasoplegia syndrome	15.58	14.04	8	8354	1848	34946721
Wrong patient received product	15.50	14.04	9	8353	2645	34945924
Cardiac pacemaker evaluation	15.46	14.04	4	8358	126	34948443
Troponin I increased	15.42	14.04	9	8353	2673	34945896
Ischaemic cerebral infarction	15.39	14.04	7	8355	1240	34947329
Rash erythematous	15.37	14.04	24	8338	24953	34923616
Neonatal pneumonia	15.31	14.04	4	8358	131	34948438
Cerebral venous thrombosis	15.21	14.04	6	8356	748	34947821
Vascular cognitive impairment	14.74	14.04	3	8359	31	34948538
Coma	14.43	14.04	33	8329	45645	34902924

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	158.12	12.24	145	21599	75890	79646754
Urticaria	123.53	12.24	198	21546	185003	79537641
Pruritus	83.83	12.24	267	21477	394381	79328263
Toxic skin eruption	83.52	12.24	60	21684	22233	79700411
Dermatitis bullous	76.62	12.24	48	21696	14197	79708447
Endocrine ophthalmopathy	72.46	12.24	20	21724	708	79721936
Nasal ulcer	69.54	12.24	25	21719	2115	79720529
Eosinophilia	63.80	12.24	70	21674	45275	79677369
Rash maculo-papular	62.85	12.24	77	21667	56001	79666643
Eczema	60.91	12.24	65	21679	40753	79681891
Death	58.07	12.24	42	21702	566472	79156172
Intentional overdose	56.95	12.24	103	21641	105857	79616787
Allergy test positive	54.44	12.24	16	21728	712	79721932
Toxic shock syndrome	53.76	12.24	18	21726	1231	79721413
Erythema	46.32	12.24	150	21594	223140	79499504
Eyelid disorder	45.69	12.24	18	21726	1960	79720684
Troponin T increased	44.75	12.24	21	21723	3501	79719143
Hallucination, auditory	44.01	12.24	40	21704	20653	79701991
Drug reaction with eosinophilia and systemic symptoms	43.17	12.24	69	21675	64175	79658469
Completed suicide	40.02	12.24	9	21735	245758	79476886
Cholestasis	37.84	12.24	58	21686	52051	79670593
Arrhythmia	37.38	12.24	63	21681	61209	79661435
Swelling of eyelid	37.26	12.24	19	21725	3792	79718852
Terminal dribbling	37	12.24	6	21738	11	79722633
Hepatic cytolysis	36.61	12.24	41	21703	27110	79695534
Electrocardiogram QT prolonged	34.29	12.24	76	21668	90310	79632334
Face oedema	33.75	12.24	40	21704	28096	79694548
Rash erythematous	33.40	12.24	58	21686	57711	79664933
Aggression	33.24	12.24	54	21690	50904	79671740
Rheumatoid arthritis	33.21	12.24	8	21736	208462	79514182
Hyperkaliuria	32.89	12.24	8	21736	170	79722474
Mean cell haemoglobin increased	32.40	12.24	18	21726	4267	79718377
Hyponatraemia	32.04	12.24	114	21630	177734	79544910
Drug intolerance	32.02	12.24	16	21728	264103	79458541
Hepatic haematoma	31.56	12.24	11	21733	850	79721794
Blood immunoglobulin E increased	29.58	12.24	19	21725	5863	79716781
Somnolence	29.34	12.24	136	21608	238845	79483799
Corneal abscess	29.15	12.24	6	21738	57	79722587
Oral dysaesthesia	27.01	12.24	7	21737	194	79722450
Acute generalised exanthematous pustulosis	26.66	12.24	28	21716	17226	79705418
Cerebral thrombosis	26.58	12.24	13	21731	2374	79720270
Gestational hypertension	26.36	12.24	12	21732	1867	79720777
Paranoia	25.61	12.24	29	21715	19403	79703241
N-terminal prohormone brain natriuretic peptide increased	25.51	12.24	16	21728	4739	79717905
Hepatocellular injury	25.21	12.24	46	21698	47547	79675097
Xerosis	24.48	12.24	10	21734	1196	79721448
Coma	23.98	12.24	71	21673	100578	79622066
Victim of chemical submission	23.91	12.24	8	21736	546	79722098
Nightmare	23.47	12.24	32	21712	25829	79696815
Prurigo	23.26	12.24	10	21734	1359	79721285
Oedema genital	23.21	12.24	8	21736	598	79722046
Abortion	22.97	12.24	10	21734	1400	79721244
Burn oral cavity	22.58	12.24	5	21739	69	79722575
Type IV hypersensitivity reaction	22.57	12.24	14	21730	4067	79718577
Synovial cyst	22.47	12.24	20	21724	10045	79712599
Acute kidney injury	22.36	12.24	228	21516	519176	79203468
Skin dystrophy	22.26	12.24	5	21739	74	79722570
Therapeutic product effect incomplete	21.48	12.24	6	21738	141639	79581005
Vitamin D decreased	21.07	12.24	19	21725	9706	79712938
Platelet count decreased	20.46	12.24	14	21730	194650	79527994
Bulbar palsy	20.39	12.24	6	21738	268	79722376
Oxalosis	20.39	12.24	5	21739	110	79722534
HLA-B*27 positive	20.35	12.24	5	21739	111	79722533
Hyperkalaemia	20.30	12.24	73	21671	114325	79608319
Abortion spontaneous	20.24	12.24	32	21712	29475	79693169
Rhabdomyolysis	20.20	12.24	68	21676	103063	79619581
Hypercholesterolaemia	20.09	12.24	28	21716	23067	79699577
Vertigo	19.67	12.24	52	21692	69030	79653614
Tooth injury	19.51	12.24	10	21734	2018	79720626
Wound	19.42	12.24	4	21740	116175	79606469
Onycholysis	19.25	12.24	10	21734	2073	79720571
Purpura	19.00	12.24	25	21719	19502	79703142
Type III immune complex mediated reaction	18.62	12.24	7	21737	671	79721973
Fixed eruption	18.56	12.24	11	21733	2943	79719701
Therapeutic product effect decreased	18.29	12.24	11	21733	163852	79558792
Miosis	18.20	12.24	22	21722	15767	79706877
Dyslipidaemia	18.19	12.24	19	21725	11614	79711030
Haemorrhagic erosive gastritis	18.04	12.24	7	21737	732	79721912
White blood cell count decreased	17.92	12.24	15	21729	188273	79534371
Arthrodesis	17.90	12.24	10	21734	2397	79720247
Eye infection	17.80	12.24	19	21725	11901	79710743
Pelvic pain	17.68	12.24	20	21724	13361	79709283
Tongue oedema	17.62	12.24	15	21729	7102	79715542
Urticaria thermal	17.53	12.24	6	21738	439	79722205
Dermatitis exfoliative	17.50	12.24	18	21726	10811	79711833
Disease prodromal stage	17.46	12.24	4	21740	65	79722579
Dermatitis exfoliative generalised	17.40	12.24	15	21729	7226	79715418
Guttate psoriasis	17.24	12.24	6	21738	461	79722183
Disease progression	17.16	12.24	15	21729	184347	79538297
Keratitis	17.03	12.24	12	21732	4310	79718334
Cerebral venous thrombosis	16.65	12.24	10	21734	2743	79719901
Poisoning deliberate	16.63	12.24	23	21721	18805	79703839
Urine oxalate increased	16.57	12.24	5	21739	244	79722400
Dyspepsia	16.51	12.24	66	21678	108621	79614023
Inflammatory bowel disease	16.27	12.24	13	21731	5638	79717006
Photosensitivity reaction	16.02	12.24	24	21720	21103	79701541
Hypersensitivity vasculitis	15.91	12.24	14	21730	6929	79715715
Urticaria chronic	15.72	12.24	6	21738	600	79722044
Myoglobin blood increased	15.41	12.24	10	21734	3141	79719503
Hyperoxaluria	15.28	12.24	5	21739	318	79722326
Systemic lupus erythematosus	15.19	12.24	7	21737	121142	79601502
Conjunctivitis allergic	15.16	12.24	8	21736	1712	79720932
Rash pustular	15.11	12.24	17	21727	11294	79711350
Cholangiocarcinoma	14.89	12.24	9	21735	2497	79720147
Pancreatitis acute	14.79	12.24	38	21706	49566	79673078
Cardiac pacemaker evaluation	14.73	12.24	4	21740	133	79722511
Serum amyloid A protein increased	14.67	12.24	5	21739	361	79722283
Alopecia areata	14.64	12.24	8	21736	1835	79720809
Upper respiratory tract infection bacterial	14.51	12.24	4	21740	141	79722503
Anaphylactic shock	14.48	12.24	31	21713	35965	79686679
Hyperlipasaemia	14.48	12.24	7	21737	1247	79721397
Arteriospasm coronary	14.31	12.24	13	21731	6703	79715941
Vascular cognitive impairment	14.18	12.24	3	21741	33	79722611
Sepsis	14.09	12.24	33	21711	269395	79453249
Drug dose titration not performed	14.03	12.24	6	21738	804	79721840
Dermatitis psoriasiform	13.99	12.24	9	21735	2785	79719859
Rhinitis allergic	13.99	12.24	17	21727	12252	79710392
Asthma	13.80	12.24	73	21671	135022	79587622
Altered state of consciousness	13.51	12.24	34	21710	43788	79678856
Retinopathy	13.50	12.24	10	21734	3881	79718763
Febrile neutropenia	13.15	12.24	27	21717	230972	79491672
Suicide attempt	13.11	12.24	51	21693	82881	79639763
Bunion operation	13.10	12.24	6	21738	946	79721698
Coronavirus infection	13.10	12.24	13	21731	7484	79715160
Feeding disorder	13.09	12.24	19	21725	16235	79706409
Lip oedema	13.02	12.24	12	21732	6304	79716340
Acute haemorrhagic oedema of infancy	12.51	12.24	3	21741	60	79722584
Pemphigoid	12.48	12.24	18	21726	15297	79707347
Drug level increased	12.48	12.24	31	21713	39620	79683024

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R06AX27	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Other antihistamines for systemic use
FDA MoA	N0000000190	Histamine H1 Receptor Antagonists
FDA EPC	N0000175587	Histamine-1 Receptor Antagonist
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D039563	Histamine H1 Antagonists, Non-Sedating
MeSH PA	D018377	Neurotransmitter Agents
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:48873	acetylcholine receptor antagonist
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:50857	anti-allergic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Vasomotor rhinitis	indication	8229003	DOID:4730
Allergic urticaria	indication	40178009	DOID:10612
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Sneezing	indication	76067001
Common cold	indication	82272006	DOID:10459
Chronic idiopathic urticaria	indication	302162004
Seasonal allergic rhinitis	indication	367498001
Allergic conjunctivitis	indication	473460002	DOID:11204
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Diabetes mellitus	contraindication	73211009	DOID:9351
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.92	Basic
pKa2	2.48	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	9.40	WOMBAT-PK	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.91	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.96	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	8.03	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.55	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.80	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.00	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.01	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.19	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.97	DRUG MATRIX
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		IC50	4.80	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	7.74	WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.60	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.49	WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.70	WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.30	WOMBAT-PK
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.51	DRUG MATRIX
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.37	WOMBAT-PK
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.70	DRUG MATRIX

External reference:

ID	Source
4021292	VUID
N0000148729	NUI
D03693	KEGG_DRUG
275635	RXNORM
4021292	VANDF
C0908935	UMLSCUI
CHEBI:291342	CHEBI
CHEMBL1172	ChEMBL_ID
DB00967	DRUGBANK_ID
C121345	MESH_SUPPLEMENTAL_RECORD_UI
124087	PUBCHEM_CID
7157	IUPHAR_LIGAND_ID
7817	INN_ID
FVF865388R	UNII
16243	MMSL
42606	MMSL
51632	MMSL
83662	MMSL
d04785	MMSL
009081	NDDF
134506008	SNOMEDCT_US
396015008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	21695-815	TABLET, FILM COATED	5 mg	ORAL	NDA	23 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	42291-240	TABLET	5 mg	ORAL	ANDA	26 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0765	TABLET, FILM COATED	5 mg	ORAL	NDA	29 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3975	TABLET	5 mg	ORAL	ANDA	32 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3975	TABLET	5 mg	ORAL	ANDA	32 sections
DESLORATADINE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4794	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
DESLORATADINE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4794	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4624	TABLET, FILM COATED	5 mg	ORAL	NDA	12 sections
Clarinex-D 12 Hour	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5708	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	29 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	55111-360	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	26 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	55111-551	TABLET, ORALLY DISINTEGRATING	2.50 mg	ORAL	ANDA	26 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	62250-619	TABLET	5 mg	ORAL	ANDA	25 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	62250-619	TABLET	5 mg	ORAL	ANDA	25 sections
Desloratadine	Human Prescription Drug Label	1	62756-523	TABLET, FILM COATED	5 mg	ORAL	ANDA	28 sections
DESLORATADINE	HUMAN PRESCRIPTION DRUG LABEL	1	68180-153	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
DESLORATADINE	HUMAN PRESCRIPTION DRUG LABEL	1	68180-153	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	69543-107	TABLET	5 mg	ORAL	ANDA	29 sections
DESLORATADINE	HUMAN PRESCRIPTION DRUG LABEL	1	71335-1000	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	78206-119	TABLET, FILM COATED	5 mg	ORAL	NDA	30 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	78206-119	TABLET, FILM COATED	5 mg	ORAL	NDA	30 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	78206-119	TABLET, FILM COATED	5 mg	ORAL	NDA	30 sections
CLARINEX-D 12 HOUR	HUMAN PRESCRIPTION DRUG LABEL	2	78206-120	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	29 sections
CLARINEX-D 12 HOUR	HUMAN PRESCRIPTION DRUG LABEL	2	78206-120	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	29 sections
CLARINEX-D 12 HOUR	HUMAN PRESCRIPTION DRUG LABEL	2	78206-120	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	29 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	78206-188	TABLET, FILM COATED	5 mg	ORAL	NDA	30 sections